{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:49:29Z","timestamp":1792532969840,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.eprac.2024.08.012","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T04:50:25Z","timestamp":1724993425000},"page":"1166-1170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Significance of Thyroid Autoantibodies in Differential Diagnosis and Predicting the Course of Programmed Cell Death Protein-1 Inhibitor-Induced Thyroid Dysfunction"],"prefix":"10.1016","volume":"30","author":[{"given":"Li","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangming","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.eprac.2024.08.012_bib1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.eprac.2024.08.012_bib2","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.eprac.2024.08.012_bib3","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.eprac.2024.08.012_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40261-018-0735-0","article-title":"Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS","volume":"39","author":"Ji","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.012_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.eprac.2024.08.012_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2024.08.012_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1016\/j.eprac.2024.08.012_bib8","article-title":"Management of thyrotoxicosis induced by PD1 or PD-L1 blockade","volume":"5","author":"Brancatella","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.012_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"12","key":"10.1016\/j.eprac.2024.08.012_bib10","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.eprac.2024.08.012_bib11","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"7","key":"10.1016\/j.eprac.2024.08.012_bib12","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.eprac.2024.08.012_bib13","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2024.08.012_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2024.08.012_bib15","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.eprac.2024.08.012_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/s-0042-119528","article-title":"Hypothyroidism in cancer patients on immune checkpoint inhibitors with anti-PD1 agents: insights on underlying mechanisms","volume":"125","author":"Alhusseini","year":"2017","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.012_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-19-0535","article-title":"Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase","volume":"182","author":"Bai","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2024.08.012_bib18","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2024.08.012_bib19","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.012_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1375642","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer","volume":"7","author":"Kim","year":"2017","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.eprac.2024.08.012_bib21","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2024.08.012_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J\u00a0Endocr Soc"},{"issue":"2","key":"10.1016\/j.eprac.2024.08.012_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5455\/medarh.2014.68.79-81","article-title":"Association between autoantibodies against thyroid stimulating hormone receptor and thyroid diseases","volume":"68","author":"Latifi-Pupovci","year":"2014","journal-title":"Med Arch"},{"issue":"4S Suppl 1","key":"10.1016\/j.eprac.2024.08.012_bib24","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/IOP.0000000000001052","article-title":"Thyrotropin receptor antibodies-an overview","volume":"34","author":"Kotwal","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"10","key":"10.1016\/j.eprac.2024.08.012_bib25","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1089\/thy.2017.0062","article-title":"Anti-PD-1 antibody therapy induces Hashimoto's disease with an increase in peripheral blood follicular helper T cells","volume":"27","author":"Torimoto","year":"2017","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.eprac.2024.08.012_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216954","article-title":"Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab","volume":"14","author":"Yamauchi","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.eprac.2024.08.012_bib27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.eprac.2024.08.012_bib28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40618-017-0772-1","article-title":"Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution","volume":"41","author":"Guaraldi","year":"2018","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"4","key":"10.1016\/j.eprac.2024.08.012_bib29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.15537\/smj.2016.4.13571","article-title":"Pattern of thyroid, celiac, and anti-cyclic citrullinated peptide autoantibodies coexistence with type 1 diabetes mellitus in patients from Southwestern Saudi Arabia","volume":"37","author":"Al-Hakami","year":"2016","journal-title":"Saudi Med J"},{"issue":"2","key":"10.1016\/j.eprac.2024.08.012_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2400661X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2400661X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T09:38:31Z","timestamp":1733132311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2400661X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1530891X2400661X"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.08.012","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Significance of Thyroid Autoantibodies in Differential Diagnosis and Predicting the Course of Programmed Cell Death Protein-1 Inhibitor-Induced Thyroid Dysfunction","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}